Andrew Schiermeier - Net Worth and Insider Trading
Andrew Schiermeier Net Worth
The estimated net worth of Andrew Schiermeier is at least $378,591 dollars as of 2024-06-09. Andrew Schiermeier is the EVP, COO of Intellia Therapeutics Inc and owns about 16,656 shares of Intellia Therapeutics Inc (NTLA) stock worth over $378,591. Details can be seen in Andrew Schiermeier's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that Andrew Schiermeier has not made any transactions after 2021-01-05 and currently still holds the listed stock(s).
Transaction Summary of Andrew Schiermeier
Andrew Schiermeier Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Andrew Schiermeier owns 1 companies in total, including Intellia Therapeutics Inc (NTLA) .
Click here to see the complete history of Andrew Schiermeier’s form 4 insider trades.
Insider Ownership Summary of Andrew Schiermeier
| Ticker | Comapny | Transaction Date | Type of Owner |
|---|---|---|---|
| NTLA | Intellia Therapeutics Inc | 2021-01-05 | EVP & Chief Operating Officer |
Andrew Schiermeier Latest Holdings Summary
Andrew Schiermeier currently owns a total of 1 stock. Andrew Schiermeier owns 16,656 shares of Intellia Therapeutics Inc (NTLA) as of January 5, 2021, with a value of $378,591.
Latest Holdings of Andrew Schiermeier
| Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
|---|---|---|---|---|---|
| NTLA | Intellia Therapeutics Inc | 2021-01-05 | 16,656 | 22.73 | 378,591 |
Holding Weightings of Andrew Schiermeier
Andrew Schiermeier Form 4 Trading Tracker
According to the SEC Form 4 filings, Andrew Schiermeier has made a total of 1 transactions in Intellia Therapeutics Inc (NTLA) over the past 5 years, including 0 buys and 1 sells. The most-recent trade in Intellia Therapeutics Inc is the sale of 1,377 shares on January 5, 2021, which brought Andrew Schiermeier around $76,919.
Insider Trading History of Andrew Schiermeier
- 1
Andrew Schiermeier Trading Performance
GuruFocus tracks the stock performance after each of Andrew Schiermeier's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Andrew Schiermeier is -8.24%. GuruFocus also compares Andrew Schiermeier's trading performance to market benchmark return within the same time period. The performance of stocks bought by Andrew Schiermeier within 3 months outperforms 0 times out of 1 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how Andrew Schiermeier's insider trading performs compared to the benchmark.
Performance of Andrew Schiermeier
Average Return
Outperforming Transactions
| 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | 3 Years | |
|---|---|---|---|---|---|---|
| Return(%) | 18.47 | | | | | |
| Relative Return to S&P 500(%) | 14.09 | | | | | |
Andrew Schiermeier Ownership Network
Andrew Schiermeier Owned Company Details
What does Intellia Therapeutics Inc do?
Who are the key executives at Intellia Therapeutics Inc?
Andrew Schiermeier is the EVP & Chief Operating Officer of Intellia Therapeutics Inc. Other key executives at Intellia Therapeutics Inc include EVP & Chief Scientific Officer Laura Sepp-lorenzino , EVP & Chief Business Officer Derek Hicks , and EVP & Chief Technical Officer Eliana Clark .
Intellia Therapeutics Inc (NTLA) Insider Trades Summary
Over the past 18 months, Andrew Schiermeier made no insider transaction in Intellia Therapeutics Inc (NTLA). Other recent insider transactions involving Intellia Therapeutics Inc (NTLA) include a net sale of 11,996 shares made by Eliana Clark , a net sale of 12,645 shares made by Laura Sepp-lorenzino , and a net sale of 2,397 shares made by Muna Bhanji .
In summary, during the past 3 months, insiders sold 0 shares of Intellia Therapeutics Inc (NTLA) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 79,775 shares of Intellia Therapeutics Inc (NTLA) were sold and 0 shares were bought by its insiders, resulting in a net sale of 79,775 shares.
Intellia Therapeutics Inc (NTLA)'s detailed insider trading history can be found in Insider Trading Tracker table.
Intellia Therapeutics Inc Insider Transactions
Andrew Schiermeier Mailing Address
Above is the net worth, insider trading, and ownership report for Andrew Schiermeier. You might contact Andrew Schiermeier via mailing address: C/o Intellia Therapeutics, Inc, 40 Erie Street Ste 130, Cambridge Ma 02139.
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
